Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Motor Cortex | 17 | 2020 | 158 | 3.890 |
Why?
|
| Recovery of Function | 17 | 2020 | 506 | 2.980 |
Why?
|
| Stroke Rehabilitation | 11 | 2020 | 335 | 2.320 |
Why?
|
| Neuronal Plasticity | 13 | 2015 | 274 | 2.170 |
Why?
|
| Electric Stimulation Therapy | 6 | 2020 | 147 | 2.050 |
Why?
|
| Brain Injuries, Traumatic | 5 | 2021 | 105 | 1.700 |
Why?
|
| Rats, Long-Evans | 17 | 2020 | 203 | 1.510 |
Why?
|
| Brain Ischemia | 7 | 2017 | 665 | 1.310 |
Why?
|
| Stroke | 14 | 2018 | 2163 | 1.240 |
Why?
|
| Rats | 20 | 2020 | 5300 | 1.110 |
Why?
|
| Sensorimotor Cortex | 2 | 2016 | 18 | 1.030 |
Why?
|
| Gray Matter | 2 | 2017 | 57 | 1.030 |
Why?
|
| Disease Models, Animal | 14 | 2020 | 2550 | 0.970 |
Why?
|
| Physical Conditioning, Animal | 5 | 2018 | 34 | 0.940 |
Why?
|
| Motor Skills | 7 | 2015 | 88 | 0.930 |
Why?
|
| Forelimb | 8 | 2020 | 15 | 0.840 |
Why?
|
| Motor Activity | 2 | 2015 | 621 | 0.770 |
Why?
|
| Animals | 32 | 2021 | 20881 | 0.730 |
Why?
|
| Upper Extremity | 2 | 2015 | 112 | 0.720 |
Why?
|
| Neural Inhibition | 1 | 2020 | 80 | 0.700 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2020 | 124 | 0.670 |
Why?
|
| Movement | 6 | 2015 | 179 | 0.650 |
Why?
|
| Physical Therapy Modalities | 3 | 2015 | 133 | 0.590 |
Why?
|
| Motor Skills Disorders | 2 | 2015 | 7 | 0.580 |
Why?
|
| Behavior, Animal | 8 | 2020 | 470 | 0.580 |
Why?
|
| Dextroamphetamine | 2 | 2008 | 30 | 0.570 |
Why?
|
| Gliosis | 1 | 2017 | 51 | 0.570 |
Why?
|
| Genes, Mitochondrial | 1 | 2016 | 4 | 0.560 |
Why?
|
| Cerebral Cortex | 3 | 2018 | 415 | 0.550 |
Why?
|
| Astrocytes | 3 | 2018 | 270 | 0.540 |
Why?
|
| Mitochondrial Proteins | 1 | 2016 | 113 | 0.530 |
Why?
|
| Exercise Movement Techniques | 1 | 2015 | 6 | 0.520 |
Why?
|
| Restraint, Physical | 1 | 2015 | 59 | 0.510 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2017 | 239 | 0.490 |
Why?
|
| Mitochondria | 2 | 2016 | 643 | 0.490 |
Why?
|
| Functional Laterality | 4 | 2017 | 240 | 0.480 |
Why?
|
| Neostriatum | 2 | 2014 | 60 | 0.480 |
Why?
|
| Corpus Striatum | 1 | 2016 | 279 | 0.480 |
Why?
|
| Cerebral Infarction | 3 | 2015 | 103 | 0.470 |
Why?
|
| Inflammation | 2 | 2018 | 1030 | 0.450 |
Why?
|
| Postural Balance | 1 | 2014 | 93 | 0.440 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2015 | 211 | 0.430 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 1851 | 0.420 |
Why?
|
| Walking | 1 | 2015 | 241 | 0.420 |
Why?
|
| Models, Neurological | 1 | 2013 | 136 | 0.410 |
Why?
|
| Male | 25 | 2021 | 37321 | 0.400 |
Why?
|
| Brain Injuries | 1 | 2015 | 268 | 0.390 |
Why?
|
| Electric Stimulation | 4 | 2014 | 218 | 0.390 |
Why?
|
| Transcranial Magnetic Stimulation | 2 | 2018 | 413 | 0.390 |
Why?
|
| Spinal Cord | 2 | 2017 | 244 | 0.380 |
Why?
|
| Pyramidal Tracts | 3 | 2018 | 45 | 0.360 |
Why?
|
| Brain Damage, Chronic | 1 | 2008 | 25 | 0.310 |
Why?
|
| Psychomotor Performance | 2 | 2008 | 213 | 0.310 |
Why?
|
| Somatosensory Cortex | 2 | 2008 | 22 | 0.290 |
Why?
|
| Brain Mapping | 4 | 2015 | 532 | 0.280 |
Why?
|
| Infarction | 1 | 2006 | 17 | 0.270 |
Why?
|
| Physical Fitness | 1 | 2006 | 117 | 0.260 |
Why?
|
| Muscle, Skeletal | 2 | 2018 | 396 | 0.250 |
Why?
|
| Complement Activation | 3 | 2021 | 145 | 0.240 |
Why?
|
| Movement Disorders | 1 | 2005 | 58 | 0.240 |
Why?
|
| Exercise Therapy | 3 | 2015 | 183 | 0.240 |
Why?
|
| Paresis | 1 | 2005 | 78 | 0.230 |
Why?
|
| Synapses | 3 | 2021 | 222 | 0.220 |
Why?
|
| Time Factors | 5 | 2015 | 4655 | 0.190 |
Why?
|
| Exercise | 1 | 2006 | 658 | 0.180 |
Why?
|
| Receptor, trkB | 1 | 2020 | 27 | 0.180 |
Why?
|
| Analysis of Variance | 3 | 2015 | 1040 | 0.180 |
Why?
|
| Endothelin-1 | 4 | 2015 | 122 | 0.180 |
Why?
|
| Neural Pathways | 2 | 2015 | 324 | 0.180 |
Why?
|
| Brain | 2 | 2018 | 2176 | 0.170 |
Why?
|
| Isometric Contraction | 1 | 2018 | 33 | 0.150 |
Why?
|
| Ankle | 1 | 2018 | 45 | 0.150 |
Why?
|
| Treatment Outcome | 4 | 2015 | 7029 | 0.150 |
Why?
|
| Evoked Potentials, Motor | 1 | 2018 | 63 | 0.150 |
Why?
|
| Cognitive Dysfunction | 1 | 2021 | 176 | 0.150 |
Why?
|
| Complement Inactivating Agents | 1 | 2018 | 56 | 0.150 |
Why?
|
| Aging | 2 | 2014 | 911 | 0.150 |
Why?
|
| Electrodes, Implanted | 2 | 2008 | 98 | 0.140 |
Why?
|
| Gene Dosage | 1 | 2016 | 47 | 0.140 |
Why?
|
| Complement System Proteins | 1 | 2018 | 135 | 0.140 |
Why?
|
| Receptors, Opioid | 1 | 2017 | 60 | 0.140 |
Why?
|
| DNA, Mitochondrial | 1 | 2016 | 84 | 0.130 |
Why?
|
| Combined Modality Therapy | 2 | 2015 | 951 | 0.130 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2018 | 296 | 0.130 |
Why?
|
| Fibrinolytic Agents | 1 | 2018 | 377 | 0.120 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2017 | 237 | 0.120 |
Why?
|
| Nerve Net | 1 | 2017 | 181 | 0.120 |
Why?
|
| Central Nervous System Stimulants | 2 | 2008 | 221 | 0.120 |
Why?
|
| Exercise Test | 1 | 2015 | 242 | 0.120 |
Why?
|
| Vibrissae | 1 | 2014 | 6 | 0.120 |
Why?
|
| Leg | 1 | 2015 | 191 | 0.120 |
Why?
|
| Infarction, Middle Cerebral Artery | 3 | 2015 | 105 | 0.110 |
Why?
|
| Dendrites | 2 | 2018 | 44 | 0.110 |
Why?
|
| Lower Extremity | 1 | 2015 | 153 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 5 | 2021 | 2791 | 0.110 |
Why?
|
| Paralysis | 1 | 2013 | 35 | 0.110 |
Why?
|
| Feeding Behavior | 1 | 2015 | 224 | 0.110 |
Why?
|
| Presynaptic Terminals | 2 | 2015 | 34 | 0.110 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 1753 | 0.110 |
Why?
|
| Mice | 5 | 2021 | 8474 | 0.100 |
Why?
|
| Oxidative Stress | 1 | 2016 | 718 | 0.100 |
Why?
|
| Humans | 9 | 2018 | 68618 | 0.100 |
Why?
|
| Analgesics, Opioid | 1 | 2017 | 498 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2077 | 0.100 |
Why?
|
| Apoptosis | 1 | 2016 | 1641 | 0.090 |
Why?
|
| Ischemia | 1 | 2010 | 229 | 0.080 |
Why?
|
| Microglia | 2 | 2021 | 143 | 0.080 |
Why?
|
| Microelectrodes | 1 | 2008 | 16 | 0.080 |
Why?
|
| Clinical Protocols | 1 | 2008 | 172 | 0.080 |
Why?
|
| Age Factors | 2 | 2012 | 1864 | 0.080 |
Why?
|
| Complement Pathway, Alternative | 2 | 2018 | 69 | 0.070 |
Why?
|
| Neurons | 2 | 2018 | 881 | 0.070 |
Why?
|
| Behavioral Symptoms | 1 | 2007 | 32 | 0.070 |
Why?
|
| Fluoresceins | 1 | 2006 | 31 | 0.070 |
Why?
|
| Bromodeoxyuridine | 1 | 2006 | 37 | 0.070 |
Why?
|
| Synaptic Transmission | 1 | 2008 | 236 | 0.070 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2006 | 35 | 0.070 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2006 | 92 | 0.070 |
Why?
|
| Motor Neurons | 1 | 2006 | 98 | 0.070 |
Why?
|
| Cell Count | 1 | 2006 | 248 | 0.070 |
Why?
|
| Muscle Contraction | 1 | 2006 | 210 | 0.070 |
Why?
|
| Organic Chemicals | 1 | 2006 | 77 | 0.060 |
Why?
|
| Nerve Degeneration | 1 | 2006 | 134 | 0.060 |
Why?
|
| Adaptation, Physiological | 1 | 2006 | 189 | 0.060 |
Why?
|
| Action Potentials | 1 | 2006 | 223 | 0.060 |
Why?
|
| Denervation | 1 | 2005 | 23 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 848 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 1174 | 0.060 |
Why?
|
| Research Design | 1 | 2007 | 729 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 1745 | 0.050 |
Why?
|
| Phagocytosis | 1 | 2021 | 65 | 0.050 |
Why?
|
| Complement C3d | 1 | 2018 | 10 | 0.040 |
Why?
|
| Neuroprotection | 1 | 2018 | 28 | 0.040 |
Why?
|
| Rest | 1 | 2018 | 78 | 0.040 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2018 | 20 | 0.040 |
Why?
|
| Complement C3 | 1 | 2018 | 101 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2018 | 172 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2018 | 376 | 0.030 |
Why?
|
| Neuropeptides | 1 | 2017 | 106 | 0.030 |
Why?
|
| Neuroprotective Agents | 1 | 2018 | 317 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2015 | 127 | 0.030 |
Why?
|
| Muscle Strength | 1 | 2015 | 62 | 0.030 |
Why?
|
| Pain | 1 | 2017 | 472 | 0.030 |
Why?
|
| Physical Stimulation | 1 | 2012 | 67 | 0.030 |
Why?
|
| Brain Infarction | 1 | 2010 | 54 | 0.020 |
Why?
|
| Sympatholytics | 1 | 2008 | 11 | 0.020 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 1 | 2008 | 40 | 0.020 |
Why?
|
| Oxidopamine | 1 | 2008 | 42 | 0.020 |
Why?
|
| Homovanillic Acid | 1 | 2008 | 52 | 0.020 |
Why?
|
| Stereotaxic Techniques | 1 | 2008 | 35 | 0.020 |
Why?
|
| Food | 1 | 2008 | 52 | 0.020 |
Why?
|
| Observer Variation | 1 | 2008 | 330 | 0.020 |
Why?
|
| Female | 2 | 2018 | 38074 | 0.020 |
Why?
|
| Dopamine | 1 | 2008 | 474 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2008 | 2083 | 0.010 |
Why?
|
| Middle Aged | 1 | 2018 | 21147 | 0.010 |
Why?
|
| Adult | 1 | 2018 | 21403 | 0.010 |
Why?
|